We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+10.49%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$11.9B
AUM Growth
+$2.55B
(+27%)
Cap. Flow
+$1.81B
Cap. Flow
% of AUM
15.19%
Top 10 Holdings %
Top 10 Hldgs %
28.34%
Holding
1,181
New
44
Increased
774
Reduced
301
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$294M |
| 2 |
Apple
AAPL
|
+$74.6M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$68.1M |
| 4 |
Tesla
TSLA
|
+$64.9M |
| 5 |
Microsoft
MSFT
|
+$51.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$12.3M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$8.37M |
| 3 |
CLR
CONTINENTAL RESOURCES INC.
CLR
|
+$7.53M |
| 4 |
ASML
ASML
|
+$7.05M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$6.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.81% |
| 2 | Financials | 13.96% |
| 3 | Healthcare | 11.37% |
| 4 | Energy | 7.72% |
| 5 | Consumer Discretionary | 3.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Zions Bancorporation
ZION
$10.2B
| $4.98M | 0.04% |
101,229
+1,112
| +1% | +$55.6K |
|
377
Emergent Biosolutions
EBS
$373M
| $4.91M | 0.04% |
415,592
+180,609
| +77% | +$2.79M |
|
378
Palo Alto Networks
PANW
$270B
| $4.91M | 0.04% |
70,344
-19,176
| -21% | -$1.54M |
|
379
W&T Offshore
WTI
$534M
| $4.89M | 0.04% |
876,724
+139,339
| +19% | +$960K |
|
380
Krystal Biotech
KRYS
$10.1B
| $4.88M | 0.04% |
61,625
+9,369
| +18% | +$695K |
|
|
INBX
381
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $4.85M | 0.04% |
196,792
+63,793
| +48% | +$1.88M |
|
382
Allogene Therapeutics
ALLO
$649M
| $4.76M | 0.04% |
756,508
+296,677
| +65% | +$2.75M |
|
383
Atlassian
TEAM
$25.6B
| $4.68M | 0.04% |
36,364
+1,717
| +5% | +$273K |
|
384
Inovio Pharmaceuticals
INO
$55.7M
| $4.62M | 0.04% |
246,926
+49,994
| +25% | +$1.13M |
|
385
Zentalis Pharmaceuticals
ZNTL
$337M
| $4.62M | 0.04% |
229,348
+45,563
| +25% | +$980K |
|
|
AXON
386
Axon Enterprise
AXON
$42.5B
| $4.61M | 0.04% |
27,768
+4,939
| +22% | +$781K |
|
387
Recursion Pharmaceuticals
RXRX
$1.59B
| $4.6M | 0.04% |
596,067
+423,541
| +245% | +$4.15M |
|
388
Vericel Corp
VCEL
$2.35B
| $4.59M | 0.04% |
174,239
+33,248
| +24% | +$792K |
|
389
McKesson
MCK
$100B
| $4.59M | 0.04% |
12,229
+4,548
| +59% | +$1.7M |
|
390
Altria Group
MO
$114B
| $4.58M | 0.04% |
100,185
+49,613
| +98% | +$2.25M |
|
|
KDNY
391
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $4.56M | 0.04% |
174,011
+30,893
| +22% | +$684K |
|
392
Target
TGT
$65.6B
| $4.55M | 0.04% |
30,496
+12,132
| +66% | +$1.9M |
|
393
Arcutis Biotherapeutics
ARQT
$3.36B
| $4.49M | 0.04% |
303,129
+129,146
| +74% | +$2.26M |
|
394
uniQure
QURE
$3.03B
| $4.48M | 0.04% |
197,621
-12,872
| -6% | -$278K |
|
395
Mercado Libre
MELI
$95.2B
| $4.46M | 0.04% |
5,274
-2,047
| -28% | -$1.82M |
|
|
VTNR
396
DELISTED
Vertex Energy, Inc
VTNR
| $4.45M | 0.04% |
718,125
-95,610
| -12% | -$714K |
|
397
Global Payments
GPN
$23B
| $4.45M | 0.04% |
44,816
+7,148
| +19% | +$745K |
|
398
Lucid Motors
LCID
$2.88B
| $4.44M | 0.04% |
65,041
+19,309
| +42% | +$2.13M |
|
399
AstraZeneca
AZN
$263B
| $4.44M | 0.04% |
32,745
-25,220
| -44% | -$3.16M |
|
400
lululemon athletica
LULU
$13.5B
| $4.44M | 0.04% |
13,849
-6,348
| -31% | -$2.09M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2022 Portfolio in Review
As of Q4 2022, Rafferty Asset Management held 1,181 positions worth $11.9B, up 27% from $9.4B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Rafferty Asset Management deployed $1.81B of net new capital in Q4 2022, opening 44 new positions and adding to 774 existing holdings. Its largest new stake was Akero Therapeutics: 187,799 shares worth $10.3M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 38% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Microchip Technology, an estimated $12.3M trimmed.
- Rafferty Asset Management's largest Q4 2022 buy was Akero Therapeutics: 187,799 shares worth $10.3M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q4 2022, an estimated $294M increase.
- Rafferty Asset Management's biggest Q4 2022 reduction was Microchip Technology, cutting an estimated $12.3M.
- Rafferty Asset Management fully exited CONTINENTAL RESOURCES INC. in Q4 2022, selling an estimated $7.53M.
- Rafferty Asset Management's ten largest holdings make up 28% of its $11.9B portfolio in Q4 2022.
- Rafferty Asset Management opened 44 new positions and closed 61 in Q4 2022.
- Rafferty Asset Management's portfolio value rose 27% quarter-over-quarter to $11.9B.
Based on Rafferty Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.